Interestingly, we noted a significantly reduced frequency of CCR6+ cells within the circulating ILC2 fraction of CF, IBD and RA patients compared to healthy controls (Figure 1D), potentially implicating a general relevance of CCR6 for ILC2 homing into chronically inflamed tissue sites. Here, CCR6 is linked to inflammatory bowel disease.